Event-Driven Stocks

Akoya Biosciences, Inc.

AKYA

Healthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 5 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20
Revenue$81.7M$96.6M$74.9M$54.9M$42.4M
Operating income−$46.7M−$57.7M−$66.1M−$39.3M−$12.0M
Net income−$55.4M−$63.3M−$70.6M−$42.9M−$16.7M
Total assets$125.0M$180.4M$176.0M$190.9M$77.7M
Total liabilities$117.4M$126.6M$117.5M$69.6M$59.6M
Equity$7.6M$53.8M$58.6M$121.4M−$51.0M
EPS (diluted)$-1.12$-1.43$-1.87$-1.65$-9.18
Shares out.49.1M38.3M37.5M37.4M2.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
−57.2%
Net margin
−67.8%
Return on equity
−729.0%
Return on assets
−44.3%
Return on capital (ROCE)
−48.9%
Liabilities / assets
93.9%
Debt / equity
15.46×
Book value / share
$0.15
Revenue growth (YoY)
−15.5%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
-7.41distress
Accruals / assets
−9.0%clean
Beneish M-Score
-3.10normal
Piotroski F-Score
3/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
37
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 5 warning● 1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Jun 30, 20252.4M3.7-9.5%
Jun 13, 20252.6M10.6-7.0%
May 30, 20252.8M1.4+18.6%
May 15, 20252.4M13.4+12.1%
Apr 30, 20252.1M14.6+3.4%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)